Testosterone pp 473-512 | Cite as

Androgen therapy in non-gonadal disease

  • Peter Y. Liu
  • David J. Handelsman


Systemic non-gonadal disease strongly influences all four dimensions of male reproductive health — sexuality, virilisation, fertility and ageing — although these effects are not always immediately apparent. Even during ill-health, men value their reproductive health and this includes a deeply-held but often unarticulated belief that their sexual function and fertility will be preserved. Recognising such unstated but important expectations is necessary for providing satisfying medical care. Consequently the impact of systemic disease and its management on male reproductive health needs to be much better understood.


Obstructive Sleep Apnea Cluster Headache Aplastic Anemia Anabolic Steroid Myotonic Dystrophy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aasebo U, Gyltnes A, Bremnes RM, Aakvaag A, Slordal L (1993) Reversal of sexual impotence in male patients with chronic obstructive pulmonary disease and hypoxemia with long term oxygen therapy. J Steroid Biochem Molec Biol 46: 799–803PubMedGoogle Scholar
  2. Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG (1983) Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med 308: 1396–1399PubMedGoogle Scholar
  3. Albrechtsen O, Barfod B, Barfod E, Laursen NP, Nordentoft B, Yde H (1972) Hormonal treatment of arterial insufficiency in the lower extremities. Dan Med Bull 19: 157–159PubMedGoogle Scholar
  4. Alexandersen P, Haarbo J, Christiansen C (1996) The relationship of natural androgens to coronary heart disease in male: a review. Atherosclerosis 125: 1–13PubMedGoogle Scholar
  5. Ambriz R, Pizzuto J, Morales M, Chavez G, Guillen C, Aviles A (1986) Therapeutic effect of danazol on metrorrhagia in patients with idiopathic thrombocytopenic purpura ( ITP ). Nouv Rev Fr Hematol 28: 275–279PubMedGoogle Scholar
  6. Bacigalupo A, et al. (1993) Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party. Br J Haematol 83: 145–151PubMedGoogle Scholar
  7. Bagatell CJ, Bremner WJ (1995) Androgen and progestagen effects on plasma lipids. Prog Cardiovas Dis 38: 255–271Google Scholar
  8. Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ (1991) Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 17: 29–33PubMedGoogle Scholar
  9. Barrett-Connor E (1996) Pharmacology, biology, and clinical applications of androgens: Current stuatus and future prospects. In: Bhasin S, Gabelnick HL, Spieler JM, Swerdloff RS, Wang C, Kelly C (eds) New York: Wiley-Liss, pp 215–223Google Scholar
  10. Belch JJ, Madhok R, McArdle B, McLaughlin K, Kluft C, Forbes CD, Sturrock R (1986) The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol. Q J Med 58: 19–27PubMedGoogle Scholar
  11. Berger JR, Pall L, Hall CD, Simpson DM (1996) Oxandrolone in AIDS-wasting myopathy. AIDS 10: 1657–1662PubMedGoogle Scholar
  12. Berns JS, Rudnick MR, Cohen RM (1992) A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 37: 264–267PubMedGoogle Scholar
  13. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R (1996) The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335: 1–7PubMedGoogle Scholar
  14. Blarney SL, Garden OJ, Shenkin A, Carter DC (1984) Modification of postoperative nitrogen balance with preoperative anabolic steroid. Clin Nutr 2: 187–192Google Scholar
  15. Bonkovsky HL, Fiellin DA, Smith GS, Slaker DP, Simon D, Galambos JT (1991a) A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function. Am J Gastroenterol 86: 1200–1208Google Scholar
  16. Bonkovsky HL, Singh RH, Jafri IH, Fiellin DA, Smith GS, Simon D, Cotsonis GA, Slaker DP (1991b) A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. II. Short-term effects on nitrogen metabolism, metabolic balance, and nutrition. Am J Gastroenterol 86: 1209–1218PubMedGoogle Scholar
  17. Booji A, Biewenga-Booji CM, Huber-Bruning O, Cornelis C, Jacobs JW, Bijlsma JW (1996) Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis. Ann Rheum Dis 55: 811–815PubMedGoogle Scholar
  18. Branda RF, Amsden TW, Jacob HS (1977) Randomized study of nandrolone therapy for anemia due to bone marrow failure. Arch Intern Med 137: 65–69PubMedGoogle Scholar
  19. Brennemann W, Brensing KA, Leipner N, Boldt I, Klingmuller D (1994) Attempted protection of spermatogenesis from irradiation in patients with seminoma by D-Tryptophan-6 luteinizing hormone releasing hormone. Clin Investigator 72: 838–842Google Scholar
  20. Brubaker LH, Briere J, Laszlo J, Kraut E, Landaw SA, Peterson P, Goldberg J, Donovan P (1982) Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Arch Intern Med 142: 1533–1537PubMedGoogle Scholar
  21. Buchwald D, Argyres S, Easterling RE, Jr FJO, Brewer GJ, Schoomaker EB, Abbrecht PH, Williams GW, Weller JM (1977) Effect of nandrolone decanoate on the anemia of chronic hemodialysis patients. Nephron 18: 232–238PubMedGoogle Scholar
  22. Burger HG, Halles J, Nelson J (1987) Effect of combined implants of oesteradiol and testosterone on libido in postmenopausal women. Br J Med i: 936–937Google Scholar
  23. Camitta BM, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rappeport JM, Santos G, Gordon-Smith EC, Storb R (1979) A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood 53: 504–514PubMedGoogle Scholar
  24. Carson PR, Carson SA (1996) Androgen replacement therapy in women: myths and realities. Int J Fertil 41: 412–422Google Scholar
  25. Champlin RE, Ho WG, Feig SA, Winston DJ, Lenarsky C, Gale RP (1985) Do androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? A prospective randomized trial. Blood 66: 184–188PubMedGoogle Scholar
  26. Chlebowski RT, Herrold J, Ali I, Oktay E, Chlebowski JS, Ponce AT, Heber D, Block JB (1986) Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 58: 183–186PubMedGoogle Scholar
  27. Cicardi M, Castelli R, Zingale LC, Agostoni A (1997) Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 99: 194–196PubMedGoogle Scholar
  28. Cooperative Group for the Study of Aplastic and Refractory Anaemias (1979) Androgen therapy of aplastic anaemia: a prospective study of 352 cases. Scand J Haematol 22: 343–356Google Scholar
  29. Copenhagen Study Group for Liver Diseases (1986) Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. Hepatology 6: 807–813Google Scholar
  30. Cutolo M, Balleari E, Giusti M, Intra E, Accardo S (1991) Androgen replacement therapy in male patients with rheumatoid arthritis. Arthritis Rheum 34: 1–5PubMedGoogle Scholar
  31. da Cunha MF, Meistrich ML, Nader S (1987) Absence of protection by a GnRH analogue against cyclophosphamide induced testicular cytotoxicity in the mouse. Cancer Res 47: 1093–1097PubMedGoogle Scholar
  32. Davis SR, Burger HG (1996) Clinical review 82: androgens and the postmenopausal woman. J Clin Endocrinol Metab 81: 2759–2763PubMedGoogle Scholar
  33. Davis SR, McCloud P, Strauss BJG, Burger H (1995) Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas 21: 227–236PubMedGoogle Scholar
  34. Dohn K, Hvidt V, Nielsen J, Palm L (1968) Testosterone therapy in obliterating arterial lesions in the lower limbs. Angiology 19: 342–350PubMedGoogle Scholar
  35. Dow MGT, Hart DM (1983) Hormonal treatments of sexual unresponsiveness in postmenopausal women: a comparative study Br J Obstet Gynaecol 90: 361–366Google Scholar
  36. Drosos AA, van Vliet-Dascalopoulos E, Andonopoulos AP, Galanopoulou V, Skopouli FN, Moutsopoulos HM (1988) Nandrolone decanoate (deac-durabolin) in primary Sjogren’s syndrome: a double blind study. Clin Exp Rheumatol 6: 53–57PubMedGoogle Scholar
  37. El-Sadr A, Sabry AA, Abdel-Rahman M, El-Barnachawy R, Koraitim M (1990) Treatment of primary nocturnal enuresis by oral androgen mesterolone. A clinical and cystometric study. Urology 36: 331–335Google Scholar
  38. Engleson ES, Pi-Sunyer FX, Kotler DP (1995) Effects of megestrol acetate therapy on body composition and circulating testosterone concentrations in ptients with AIDS. AIDS 9: 1107–1108.Google Scholar
  39. Evans JT, Elias EG (1972) The erythropoietic response to anabolic therapy in patients receiving radiotherapy. J Clin Pharmacol New Drugs 12: 101–104PubMedGoogle Scholar
  40. Fenster LF (1966) The nonefficacy of short-term anabolic steroid therapy in alcoholic liver disease. Ann Intern Med 65: 738–744Google Scholar
  41. Foss GL (1939) Clinical administration of androgens. Lancet i: 502–504Google Scholar
  42. French Cooperative Group for the Study of Aplastic and Refractory Anaemias (1986) Androgen therapy in aplastic anaemia: a comparative study of high and low-doses and of 4 different androgens. Scand J Haematol 36: 346–352Google Scholar
  43. Friedl KE, Hannan CJ, Jones RE, Plymate SR (1990) High-density lipoprotein cholesterol is not decreased if an aromatisable androgen is administered. Metab 39: 69–74Google Scholar
  44. Gelfand JA, Sherins RJ, Ailing DW, Frank MM (1976) Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. N Engl J Me. 295: 1444–1448Google Scholar
  45. Genster HG, Oram V (1971) Medical treatment of arterial insufficiency in the lower limbs. Ugeskr Laeg 133: 244–246PubMedGoogle Scholar
  46. Geusens P, Dequeker J (1986) Long-term effect of nandrolone decanoate, la-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study. Bone and Mineral 1: 347–357PubMedGoogle Scholar
  47. Gill PS, Lunardi-Ishkandar Y, Louie S, Tulpule A, Zheng T, Espina BM, Besnier JM, Hermans P, Levine AM, Bryant JL, Gallo RC (1996) The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi’s sarcoma. N Engl J Med 335: 1261–1269PubMedGoogle Scholar
  48. Glode LM, Robinson J, Gould SF (1981) Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotrophin-releasing hormone. Lancet 1: 1132–1134PubMedGoogle Scholar
  49. Gluud C, Bennett P, Dietrichson O, Johnsen SG, Ranek L, Svendsen LB, Juhl E (1981) Short- term parenteral and peroral testosterone administration in men with alcoholic cirrhosis. Scand J Gastro 16: 749–755Google Scholar
  50. Gluud C, Bennett P, Svenstrup B, Micic S, Copenhagen Study Group for Liver Diseases (1988 a) Effect of oral testosterone treatment on serum concentrations of sex steroids, gonadotrophins and prolactin in alcoholic cirrhotic men. Aliment Pharmacol Therap 2: 119–128Google Scholar
  51. Gluud C, Wantzin P, Eriksen J, Copenhagen Study Group for Liver Diseases (1988 b) No effect of oral testosterone treatment on sexual dysfunction in alcoholic cirrhotic men. Gastroenterology 95: 1582–1587Google Scholar
  52. Gluud C, Christoffersen P, Eriksen J, Wantzin P, Knudsen BB, Copenhagen Study Group for Liver Diseases (1987 a) No effect of long-term oral testosterone treatment on liver morphology in men with alcoholic cirrhosis. Am J Gastroenterol 82: 660–664PubMedGoogle Scholar
  53. Gluud C, Dejgard A, Bennett P, Svenstrup B (1987 b) Androgens and oestrogens before and following oral testosterone administraton in male patients with and without alcoholic cirrhosis. Acta Endocrinol 115: 385–391PubMedGoogle Scholar
  54. Gluud C, Henricksen JH, Copenhagen Study Group for Liver Diseases (1987 c) Liver haemo-dynamics and function in alcoholic cirrhosis. J Hepatol 4: 168–173Google Scholar
  55. Gold J, High HA, Li Y, Michelmore H, Bodsworth NJ, Finlayson R, Furner VL, Allen BJ, Oliver CJ (1996) Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS 10: 745–752PubMedGoogle Scholar
  56. Greenblatt RB, Barfield WE, Garner JF, Calk GL, Harrod JP (1950) Evaluation of an estrogen, androgen, estrogen-androgen combination, and a placebo in the treatment of the menopause. J Clin Endocrinol Metab 10: 1547–1558PubMedGoogle Scholar
  57. Griggs RC, Kingston W, Herr BE, Forbes G, Moxley RT (1985) Lack of relationship of hypogonadism to muscle wasting in myotonic dystrophy. Arch Neurol 42: 881–885PubMedGoogle Scholar
  58. Griggs RC, Pandya S, Florence JM, Brooke MH, Kingston W, Miller JP, Chutkow J, Herr BE, Moxley RT (1989) Randomized controlled trial of testosterone in myotonic dystrophy. Neurology 39: 219–222PubMedGoogle Scholar
  59. Grunfeld C, Feingold KR (1992) Metabolic disturbances and wasting in the Acquired Immunodeficiency Syndrome. N Engl J Med 327: 329–37PubMedGoogle Scholar
  60. Grunstein RR, Handeisman DJ, Lawrence SJ, Blackwell C, Caterson ID, Sullivan CE (1989) Hypothalamic dysfunction in sleep apnea: reversal by nasal continuous positive airways pressure. J Clin Endocrinol Metab 68: 352–358PubMedGoogle Scholar
  61. Hall GM, Larbre JP, Spector TD, Perry LA, Silva JAD (1996) A randomized trial of testosterone therapy in males with rheumatoid arthritis. Br J Rheumatol 35: 568–573PubMedGoogle Scholar
  62. Hamilton JB (1937) Treatment of sexual underdevelopment with synthetic male hormone substance. Endocrinology 21: 649–654Google Scholar
  63. Handelsman DJ (1985) Hypothalamic-pituitary gonadal dysfunction in chronic renal failure, dialysis, and renal transplantation. Endo Rev 6: 151–182Google Scholar
  64. Handelsman DJ, Dong Q (1993) Hypothalamo-pituitary gonadal axis in chronic renal failure. Endocrin Metab Clin 22: 145–161Google Scholar
  65. Handelsman DJ (1997) Testicular dysfunction in systemic diseases. In: Nieschlag E, Behre HM (eds) Andrology: Male reproductive health and dysfunction. Springer-Verlag, Berlin, pp 227–237Google Scholar
  66. Hansell DT, Davies JW, Shenkin A, Garden OJ, Burns HJ, Carter DC (1989) The effects of an anabolic steroid and peripherally administered intravenous nutrition in the early postoperative period. J Parent Ent Nutr 13: 349–358Google Scholar
  67. Hausmann DF, Nutz V, Rommelsheim K, Caspari R, Mosebach KO (1990) Anabolic steroids in polytrauma patients. Influence on renal nitrogen and amino acid losses: a double- blind study. J Parent Ent Nutr 14: 111–114Google Scholar
  68. Hazelton RA, McCruden AB, Sturrock RD, Stimson WH (1983) Hormonal manipulation of the immune response in systemic lupus erythematosus: a drug trial of an anabolic steroid, 19–nortestosterone. Ann Rheum Dis 42: 155–157PubMedGoogle Scholar
  69. Hendler ED, Goffmet JA, Ross S, Longnecker RE, Bakovic V (1974) Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis. N Engl J Med 291: 1046–1051PubMedGoogle Scholar
  70. Hengge UR, Baumann M, Maleba R, Brockmeyer NH, Goos M (1996) Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) in-fection. Br J Nutr 75: 129–138PubMedGoogle Scholar
  71. Hentzer E, Madsen PC (1967) Testosterone in the treatment of arterial insufficiency of the lower limbs. Scand J Clin Lab Invest 99: 198–206Google Scholar
  72. Hosea SW, Santaella ML, Brown EJ, Berger M, Katusha K, Frank MM (1980) Long-term therapy of hereditary angioedema with danazol. Ann Intern Med 93: 809–812PubMedGoogle Scholar
  73. Ingle JN (1984) Additive hormonal therapy in women with advanced breast cancer. Cancer 53: 766–777PubMedGoogle Scholar
  74. Inkovaara J, Gothoni G, Halttula R, Heikinheimo R, Tokola O (1983) Calcium, vitamin D and anabolic steroid in treatment of aged bones: double-blind placebo-controlled long- term clinical trial. Age and Ageing 12: 124–130PubMedGoogle Scholar
  75. Itil TM, Cora R, Akpinar S, Herrmann WM, Patterson CJ (1974) “Psychotropic” action of sex hormones: computerized EEG in establishing the immediate CNS effects of steroid hormones. Curr Therap Res 16:1147–1170Google Scholar
  76. Itil TM, Michael ST, Shapiro DM, Itil KZ (1984) The effects of mesterolone, a male sex hormone in depressed patients (a double blind controlled study). Meth and Find Exptl Clin Pharmacol 6: 331–337Google Scholar
  77. Jayson MI, Holland CD, Keegan A, Illingworth K, Taylor L (1991) A controlled study of stanozolol in primary Raynaud’s phenomenon and systemic sclerosis. Ann Rheum Dis 50: 41–47PubMedGoogle Scholar
  78. Johnson DH, Linde R, Hainsworth JD, Vale W, Rivier J, Stein R, Flexner J, R van Welch, Greco FA (1985) Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients wth lymphoma: preliminary observations. Blood 65: 832–836PubMedGoogle Scholar
  79. Joura EA, Zeisler H, Bancher-Todesca D, Sator MO, Schneider B, Gitsch G (1997) Short-term effects of topical testosterone in vulvar lichen sclerosis. Obstet Gynecol 89: 297–299PubMedGoogle Scholar
  80. Kaltwasser JP, Dix U, Schalk KP, Vogt H (1988) Effect of androgens on the response to anti- thymocyte globulin in patients with aplastic anaemia. Eur J Haematol 40: 111–118PubMedGoogle Scholar
  81. Kassmann K, Rappaport R, Broyer M (1992) The short-term effect of testosterone on growth in boys on hemodialysis. Clin Nephrol 37: 148–154PubMedGoogle Scholar
  82. Keogh A, Spratt P, McCosher C, McDonald P, Mundy J, Kaan A (1995) Ketoconazole to reduce the need for cyclosporine after cadiac transplantation. N Engl J Med 333: 628–633PubMedGoogle Scholar
  83. Kerrebijn KF, Delver A (1969) Ethylestrenol (Orgabolin): effects on asthmatic children during corticosteroid treatment. Scand J Resp Dis 68: 70–77Google Scholar
  84. Kopera H (1976) Miscellaneous uses of anabolic steroids. In: Kochakian CD (ed) Anabolic-androgenic steroids. Berlin: Springer-Verlag, pp 535–625Google Scholar
  85. Kotler DP, Tierney AR, Wang J, Pierson RN (1989) Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 50: 444–447PubMedGoogle Scholar
  86. Kreusser ED, Hetzel WD, Hautmann R, Pfeiffer EF (1990) Reproductive toxicity with and without LHRHa administration during adjuvant chemotherapy in patients with germ cell tumors. Hormon Metab Res 22: 494–498Google Scholar
  87. Kruskemper HL (1968) Anabolic steroids. Academic Press, New YorkGoogle Scholar
  88. Lahita RG, Cheng CY, Monder C, Bardin CW (1992) Experience with 19-nortestosterone in the therapy of systemic lupus erythematosus: worsened disease after treatment with 19- nortestosterone in men and lack of improvement in women. J Rheumatol 19: 547–555PubMedGoogle Scholar
  89. Lewis L, Dahn M, Kirkpatrick JR (1981) Anabolic steroid administration during nutritional support: a therapeutic controvery. J Parent Ent Nutr 5: 64–66Google Scholar
  90. Li Bock E, Fülle HH, Heimpel H, Pribilla W (1976) Die Wirkung von Mesterolon bei Panmyelopathien und renalen Anaemien. Med Klin 71: 539–547Google Scholar
  91. Lovejoy JC, Bray GA, Greeson CS, Klemperer M, Morris J, Partington C, Tulley R (1995) Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. Int J Obesity 19: 614–624Google Scholar
  92. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O (1993) Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sei 90: 11162–11166Google Scholar
  93. Maddrey WC (1986) Is therapy with testosterone or anabolic-androgenic steroids useful in the treatment of alcoholic liver disease? Hepatology 6: 1033–1035PubMedGoogle Scholar
  94. Mandelli F, Amadori S, Dini E, Grignani F, Leoni P, Liso V, Martelli M, Neri A, Petti MC, Ferrini PR (1981) Randomized clinical trial of immunotherapy and androgenotherapy for remission maintenance in acute non-lymphocytic leukemia. Leuk Res 5: 447–452PubMedGoogle Scholar
  95. Marin P (1995) Testosterone and regional fat distribution. Obesity Res 3 (Suppl 4): 609S–612SGoogle Scholar
  96. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G, Bjorntorp P (1992) The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obesity 16: 991–997Google Scholar
  97. Marin P, Oden B, Bjorntorp P (1995) Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 80: 239–243PubMedGoogle Scholar
  98. Masala A, Faedda R, Alagna A, Satta A, Chiarelli G, Rovasio PP, Ivaldi R, Taras MS, Lai E, Bartoli E (1997) Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 126: 292–295PubMedGoogle Scholar
  99. Matsumoto A, Sandblom RE, Schoene RB, Lee KA, Giblin EC, Pierson DJ, Bremner WJ (1985) Testosterone replacement in hypogonadal men: effects on obstructive sleep apnea, respiratory drives and sleep. Clin Endocrinol 22: 713–721Google Scholar
  100. McMullin GM, Watkin GT, Coleridge Smith PD, Scurr JH (1991) Efficacy of fibrinolytic enhancement with stanozolol in the treatment of venous insufficiency. Aust NZ J Surg 61: 306–309Google Scholar
  101. Mendenhall CL, Anderson S, Garcia-Pont P, Goldberg S, Kierman T, Seeff L, Sorrell M, Tamburro C, Weesner R, Zetterman R, Chedid A, Chen T, Rabin L, Veterans Administration Cooperative Study on Alcoholic Hepatitis (1984) Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prenisolone. N Engl J Med 311: 1464–1470Google Scholar
  102. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, Schiff ER, McClain CJ, Marsano LS, Allen JI (1993) A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis. Hepatology 17: 564–576PubMedGoogle Scholar
  103. Millman RP, Kimmel PL, Shore ET, Wasserstein AG (1985) Sleep apnea in hemodialysis patients: the lack of testosterone effect on its pathogenesis. Nephron 40: 407–410PubMedGoogle Scholar
  104. Morris ID (1993) Protection against cytotoxic-induced testis damage–experimental approaches. Eur Urol 23: 143–147PubMedGoogle Scholar
  105. Naik RB, Gibbons AR, Gyde OH, Harris BR, Robinson BH (1978) Androgen trial in renal anaemia. Proc Eur Dial Trans Assoc 15: 136–143Google Scholar
  106. Najean Y, Joint Group for the Study of Aplastic and Refractory Anaemias (1981) Long-term follow-up in patients with aplastic anemia. A study of 137 androgen-treated patients surviving more than two years. Am J Med 71: 543–551Google Scholar
  107. Najean Y, Pecking A (1979) Refractory anemia with excess of blast cells: prognostic factors and effect of treatment with androgens or cytosine arabinoside. Results of a prospective trial in 58 patients. Cooperative Group for the Study of Aplastic and Refractory Anemias. Cancer 44: 1976–1982PubMedGoogle Scholar
  108. Need AG, Nordin BEC, Chatterton BE (1993) Double-blind placebo-controlled trial of treatment of osteoporosis with the anabolic steroid nandrolone decanoate. Osteoporosis Int (Suppl 1 ): S218–S222Google Scholar
  109. Neff MS, Goldberg J, Slifkin RF, Eiser AR, Calamia V, Kaplan M, Baez A, Gupta S, Mattoo N (1981) A comparison of androgens for anemia in patients on hemodialysis. N Engl J Med 304: 871–875PubMedGoogle Scholar
  110. Nicolodi M, Sicuteri F, Poggioni M ( 1993 a) Hypothalamic modulation of nociception and reproduction in cluster headache. I. Therapeutic trials of leuprolide. Cephalgia 13: 253–257Google Scholar
  111. Nicolodi M, Sicuteri F, Poggioni M ( 1993 b) Hypothalamic modulation of nociception and reproduction in cluster headache. II. Testosterone-induced increase of sexual activity in males with cluster headache. Cephalgia 13: 258–260Google Scholar
  112. Nieschlag E, Clippers HJ, Wickings EJ (1977) Influence of sex, testicular development and liver function on the bioavailability of oral testosterone. Eur J Clin Invest 7: 145–147PubMedGoogle Scholar
  113. Nieschlag E, Nieschlag S, Behre HM (1993) Lifespan and testosterone. Nature 366: 215PubMedGoogle Scholar
  114. Oster MH, Enders SR, Samuels SJ, Cone LA, Hooton TM, Browder HP, Flynn NM (1994) Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 121: 400–408PubMedGoogle Scholar
  115. Paslin D (1996) Androgens in the topical treatment of lichen sclerosis. Int J Dermatol 35: 298–301PubMedGoogle Scholar
  116. Quigley CA, DeBellis A, Marschke KB, El-Awady MK, Wilson EM, French FF (1995) Androgen receptor defects: historical, clinical and molecular perspectives. Endo Rev 16: 271–321Google Scholar
  117. Rabkin JG, Rabkin R, Wagner G (1995) Testosterone replacement therapy in HIV illness. Gen Hosp Psychiat 17: 37–42Google Scholar
  118. Reid IR, Wattie DJ, Evans MC, Stapleton JP (1996) Testosterone therapy in glucocorticoid-Google Scholar
  119. treated men. Arch Intern Med 156:1173–1177Google Scholar
  120. Reid IR, Ibbertson HK, France JT, Pybus J (1985) Plasma testosterone concentrations in asthmatic men treated with glucocorticoids. Br J Med 291: 574Google Scholar
  121. Rittmaster RS (1994) Finasteride. N Engl J Med 330: 120–125Google Scholar
  122. Sandblom RE, Matsumoto AM, Scoene RB, Lee KA, Giblin EC, Bremner WJ, Pierson DJ (1983) Obstructive sleep apnea induced by testosterone administration. N Engl J Med 308: 508–510PubMedGoogle Scholar
  123. Santavirta S, Konttinen YT, Heliovaara M, Knekt P, Lüthje P, Aromaa A (1992) Determinants of osteoporotic thoracic vertebral fracture. Screening of 57,000 Finnish women and men. Acta Orthoped Scand 63: 198–202Google Scholar
  124. Savin RC (1968) The ineffectiveness of testosterone in male pattern baldness. Arch Dermatol 98: 512–514PubMedGoogle Scholar
  125. Savvas M, Studd JWW, Norman S, Leather AT, Garnett TJ (1992) Increase in bone mass after one year of percutaenous oestradiol and testosterone implants in post-menopausal women who have previously received long-term oral Östrogens. Br J Obstet Gynaecol 99: 757–760PubMedGoogle Scholar
  126. Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca A, Kotler DP, Wang J, Bozette SA, Breitmeyer JB, Serostim Study Group (1996) Recombinant human growth hormone in patients with HIV-associated wasting. Ann Intern Med 125: 873–882Google Scholar
  127. Schneider BK, Pickett CK, Zwillich CW, Weil JV, McDermott MT, Santen RJ, Varano LA, White DP (1986) Influence of testosterone on breathing during sleep. J Appl Physiol 61: 618–623PubMedGoogle Scholar
  128. Schols AM, Soeters PB, Mostert R, Pluymers RJ, Wouters EF (1995) Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 152: 1268–1274Google Scholar
  129. Shalet SM, Beardwell CG, Jacobs HS, Pearson D (1978) Testicular function following irradia-tion of the human prepubertal testis. Clin Endocrinol 9: 483–490Google Scholar
  130. Sheffer AL, Fearon DT, Austen KF (1977) Methyltestosterone therapy in hereditary angio- edema. Ann Intern Med 86: 306–308PubMedGoogle Scholar
  131. Sherwin BB, Gelfand MM (1985) Differential symptom response to parenteral estrogen and/ or androgen administration in the surgical menopause. Am J Obstet Gynecol 151: 153–160PubMedGoogle Scholar
  132. Sherwin BB, Gelfand MM (1987) The role of androgens in the maintenance of sexual func-tioning in oophorectomized women. Psychosom Med 49: 397–409PubMedGoogle Scholar
  133. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331: 1056–1061PubMedGoogle Scholar
  134. Spaulding WB (1960) Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema). Ann Intern Med 53: 739–745Google Scholar
  135. Spiers A SD, DeVita SF, Allar MJ, Richards S, Sedranak N (1981) Beneficial effects of an anabolic steroid during cytotoxic chemotherapy for metastatic cancer.J Med 12: 433–446PubMedGoogle Scholar
  136. Teruel JL, Aguilera A, Mareen R, Antolin JN, Otero GG, Ortuno J (1996a) Androgen therapy for anaemia of chronic renal failure. Scand J Urol Nephrol 30: 403–408PubMedGoogle Scholar
  137. Teruel JL, Mareen R, Navarro-Antolin J, Aguilera A, Fernandez-Juarez G, Ortuno J (1996 b) Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: prospective study. J Am Soc Nephrol 7: 140–144Google Scholar
  138. Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL, Sady MA, Herbert PN (1989) Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. J Am Med Ass 261: 1165–1168Google Scholar
  139. Tricker R, Casaburi R, Storer TW, Clevenger B, Berman N, Shirazi A, Bhasin S (1996) The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men - a clinical research center study. J Clin Endocrinol Metab 81: 3754–3758PubMedGoogle Scholar
  140. Tweedle D, Walton C, Johnston IDA (1973) The effect of an anabolic steroid on postoperative nitrogen balance. Br J Clin Practice 27: 130–132Google Scholar
  141. Urman B, Pride SM, Yuen BH (1991) Elevated serum testosterone, hirsutism, and virilism associated with combined androgen-estrogen hormone replacement therapy. Obstet Gynecol 77: 1124–1131Google Scholar
  142. van Coevorden A, Stolear JC, Dhaene M, Herweghem JLV, Mockel J (1986) Effect of chronic oral testosterone undecanoate administration on the pituitary-testicular axes of hemodialyzed male patients. Clin Nephrol 26: 48–54PubMedGoogle Scholar
  143. van Roenn JH, Armstrong D, Kotler DP, Cohn DL, Klimas NG, Tchekmedyian NS, Cone L, Brennan PJ, Weitzman SA (1994) Megesterol acetate in patients with AIDS-related cachexia. Ann Intern Med 121: 393–399Google Scholar
  144. Van Vollenhoven RF, Engleman EG, McGuire JL (1995) Dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 38: 1826–1831PubMedGoogle Scholar
  145. Watson RN, Bradley MH, Callahan R, Peters BJ, Kory RC (1959) A six-month evaluation of an anabolic drug, norethandrolone, in underweight persons. Am J Med 26: 238–248PubMedGoogle Scholar
  146. Wattel E, Cambier N, Caulier MT, Sautiere D, Bauters F, Fenaux P (1994) Androgen therapy in myelodysplastic syndromes with thrombocytopenia: a report on 20 cases. Br J Haematol 87: 205–208PubMedGoogle Scholar
  147. Waxman JH, Ahmed R, Smith D, Wrigley PFM, Gregory W, Shalet S, Crowther D, Rees LH, Besser GM, Malpas JS, Lister TA (1987) Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol 19: 159–162PubMedGoogle Scholar
  148. Webb WR, Doyle RS, Howard HS (1960) Relative metabolic effects of calories, protein, and an anabolic steroid (19-nortestosterone) in early postoperative period. Metabolism 9: 1047–1057PubMedGoogle Scholar
  149. Wells R (1960) Prednisolone and testosterone propionate in cirrhosis of the liver: a controlled trial. Lancet ii: 1416–1419Google Scholar
  150. Williams JS, Stein JH, Ferris TF (1974) Nandrolone decanoate therapy for patients receiving hemodialysis. A controlled study. Arch Intern Med 134: 289–292PubMedGoogle Scholar
  151. Wu S, Weng X, (1993) Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J 106: 415–418PubMedGoogle Scholar
  152. Young GA, Yule AG, Hill GL (1983) Effects of an anabolic steroid on plasma amino acids, proteins, and body composition in patients receiving intravenous hyperalimentation. J Parent Ent Nutr 7: 221–225Google Scholar
  153. Young N, Griffith P, Brittain E, Elfenbein G, Gardner F, Huang A, Harmon D, Hewlett J, Fay J, Mangan K (1988) A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood 72: 1861–1869PubMedGoogle Scholar
  154. Zawilska K, et al. (1990) Nebulised heparin and anabolic steroid in the prevention of postoperative deep venous thrombosis following elective abdominal surgery. Folia Haemato- logica 117: 699–707Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • Peter Y. Liu
  • David J. Handelsman

There are no affiliations available

Personalised recommendations